• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
Icon-twitter-x Youtube Facebook Linkedin Instagram

Frequently Asked Questions (FAQ):

  • Can people from any country in the EU participate?

Currently the countries participating in the RESILIENCE project are: Spain with 13 associated centers, France, Portugal, Germany, Denmark and the Netherlands. Click here if you would like to know more!

  • Will the clinical trial be open to patients with other types of cancer?

The trial is currently intended to study only lymphoma. We hope that in the future, patients with other types of cancer may benefit.

  • What is the age range to participate in this trial?

Patients eligible to participate in the trial must be 18 years of age or older. In fact, being over the age of 65 is considered a risk factor for developing cardiotoxicity.

  • Does the intervention have side effects?

The intervention has been studied in other clinical trials, such as the CONDI-2 study, which shows that the therapy is safe, since no serious adverse effect related to it was reported in more than 5,000 patients.

  • What are the requirements to participate in the trial?

Your doctor will ensure that you meet the study inclusion criteria. Among them are that it is your first treatment with anthracyclines or that there is no contraindication to be able to do the MRIs.

  • I would like to know how the project is doing, is the treatment working?

In order to determine if the treatment is working in patients with lymphoma, we still have a long way to go. We rely on the evidence of its benefits in the animal model and in other pathologies such as myocardial infarction. We continue working to advance in the benefit of our patients.

Resilience

Cardiac Magnetic Resonance

  • Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

Clinical Trial Synopsis

  • Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning.

For patients

Legals

Follow Us

Twitter Youtube Facebook Linkedin Instagram
  • This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions